Thus, counteracting raised Bace1 activity associated with chronic HFD will play a critical protective role against metabolic disease and suggest that pharmacological approaches, including repurposing of Bace1 inhibitors currently being developed for AD, represent a novel strategy for the treatment of obesity and T2D. Here, BACE1 is linked to obesity due to melanocortin 4 receptor deficiency.